Influence of treatment modality in outcomes for different stages of resectable esophageal adenocarcinomas

Bassan J. Allan, Felipe Pedroso, Elisabeth R. Gennis, Alan S. Livingstone, Alberto Montero, Brian Lally, Bach Ardalan, Leonidas Koniaris, Naveenraj L. Solomon, Dido Franceschi

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: There is no consensus on the most effective modality for the treatment of resectable esophageal adenocarcinomas (EAC). We theorized that treatment modality may influence survival differently depending on the stage of disease. Methods: A single-institution, retrospective examination of resectable EAC between 2000 and 2008 was performed. Resectable EAC were stratified into early disease (stage 2a or less) and late disease (stage 2b or more) based on pretreatment endoscopic ultrasound (EUS). Patients with T4, >N2, and/or distant disease were excluded. Results: A total of 156 patients were included in this study. Most patients were white (97 %), male (83 %), and over 60 years of age (51 %). Patients with early disease on pretreatment EUS exhibited improved overall survival compared to patients with late disease (P <0.001). Irrespective of treatment modality, there were no significant differences in overall 5-year survival for patients with early or late disease. Early and late disease patients whose disease responded to neoadjuvant chemotherapy (NAC) had significantly improved overall survival compared to nonresponsive disease (P <0.05). The only negative independent predictors of overall 5-year survival were late stage disease on pretreatment EUS (hazard ratio 2.402, 95 % confidence interval 1.24-4.67, P = 0.01) and late stage disease on final pathological stage (hazard ratio 2.29, 95 % confidence interval 1.22-4.31, P = 0.01). Conclusions: Our data lack statistical power but reveal no difference in survival with the addition of neoadjuvant therapies to surgery for early or late resectable EAC. However, patients with disease that responded to NAC had improved outcomes at 5 years for both groups. Therefore, the prognosis for patients undergoing NAC may be optimized by immediate surgical resection if neoadjuvant therapies do not result in a dramatic clinical response.

Original languageEnglish (US)
Pages (from-to)1660-1667
Number of pages8
JournalAnnals of Surgical Oncology
Volume20
Issue number5
DOIs
StatePublished - May 2013
Externally publishedYes

Fingerprint

Adenocarcinoma
Survival
Therapeutics
Neoadjuvant Therapy
Drug Therapy
Confidence Intervals

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Allan, B. J., Pedroso, F., Gennis, E. R., Livingstone, A. S., Montero, A., Lally, B., ... Franceschi, D. (2013). Influence of treatment modality in outcomes for different stages of resectable esophageal adenocarcinomas. Annals of Surgical Oncology, 20(5), 1660-1667. https://doi.org/10.1245/s10434-012-2766-8

Influence of treatment modality in outcomes for different stages of resectable esophageal adenocarcinomas. / Allan, Bassan J.; Pedroso, Felipe; Gennis, Elisabeth R.; Livingstone, Alan S.; Montero, Alberto; Lally, Brian; Ardalan, Bach; Koniaris, Leonidas; Solomon, Naveenraj L.; Franceschi, Dido.

In: Annals of Surgical Oncology, Vol. 20, No. 5, 05.2013, p. 1660-1667.

Research output: Contribution to journalArticle

Allan, BJ, Pedroso, F, Gennis, ER, Livingstone, AS, Montero, A, Lally, B, Ardalan, B, Koniaris, L, Solomon, NL & Franceschi, D 2013, 'Influence of treatment modality in outcomes for different stages of resectable esophageal adenocarcinomas', Annals of Surgical Oncology, vol. 20, no. 5, pp. 1660-1667. https://doi.org/10.1245/s10434-012-2766-8
Allan, Bassan J. ; Pedroso, Felipe ; Gennis, Elisabeth R. ; Livingstone, Alan S. ; Montero, Alberto ; Lally, Brian ; Ardalan, Bach ; Koniaris, Leonidas ; Solomon, Naveenraj L. ; Franceschi, Dido. / Influence of treatment modality in outcomes for different stages of resectable esophageal adenocarcinomas. In: Annals of Surgical Oncology. 2013 ; Vol. 20, No. 5. pp. 1660-1667.
@article{10fe7433a8e6406e8c93988fcc6a6ac7,
title = "Influence of treatment modality in outcomes for different stages of resectable esophageal adenocarcinomas",
abstract = "Background: There is no consensus on the most effective modality for the treatment of resectable esophageal adenocarcinomas (EAC). We theorized that treatment modality may influence survival differently depending on the stage of disease. Methods: A single-institution, retrospective examination of resectable EAC between 2000 and 2008 was performed. Resectable EAC were stratified into early disease (stage 2a or less) and late disease (stage 2b or more) based on pretreatment endoscopic ultrasound (EUS). Patients with T4, >N2, and/or distant disease were excluded. Results: A total of 156 patients were included in this study. Most patients were white (97 {\%}), male (83 {\%}), and over 60 years of age (51 {\%}). Patients with early disease on pretreatment EUS exhibited improved overall survival compared to patients with late disease (P <0.001). Irrespective of treatment modality, there were no significant differences in overall 5-year survival for patients with early or late disease. Early and late disease patients whose disease responded to neoadjuvant chemotherapy (NAC) had significantly improved overall survival compared to nonresponsive disease (P <0.05). The only negative independent predictors of overall 5-year survival were late stage disease on pretreatment EUS (hazard ratio 2.402, 95 {\%} confidence interval 1.24-4.67, P = 0.01) and late stage disease on final pathological stage (hazard ratio 2.29, 95 {\%} confidence interval 1.22-4.31, P = 0.01). Conclusions: Our data lack statistical power but reveal no difference in survival with the addition of neoadjuvant therapies to surgery for early or late resectable EAC. However, patients with disease that responded to NAC had improved outcomes at 5 years for both groups. Therefore, the prognosis for patients undergoing NAC may be optimized by immediate surgical resection if neoadjuvant therapies do not result in a dramatic clinical response.",
author = "Allan, {Bassan J.} and Felipe Pedroso and Gennis, {Elisabeth R.} and Livingstone, {Alan S.} and Alberto Montero and Brian Lally and Bach Ardalan and Leonidas Koniaris and Solomon, {Naveenraj L.} and Dido Franceschi",
year = "2013",
month = "5",
doi = "10.1245/s10434-012-2766-8",
language = "English (US)",
volume = "20",
pages = "1660--1667",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "5",

}

TY - JOUR

T1 - Influence of treatment modality in outcomes for different stages of resectable esophageal adenocarcinomas

AU - Allan, Bassan J.

AU - Pedroso, Felipe

AU - Gennis, Elisabeth R.

AU - Livingstone, Alan S.

AU - Montero, Alberto

AU - Lally, Brian

AU - Ardalan, Bach

AU - Koniaris, Leonidas

AU - Solomon, Naveenraj L.

AU - Franceschi, Dido

PY - 2013/5

Y1 - 2013/5

N2 - Background: There is no consensus on the most effective modality for the treatment of resectable esophageal adenocarcinomas (EAC). We theorized that treatment modality may influence survival differently depending on the stage of disease. Methods: A single-institution, retrospective examination of resectable EAC between 2000 and 2008 was performed. Resectable EAC were stratified into early disease (stage 2a or less) and late disease (stage 2b or more) based on pretreatment endoscopic ultrasound (EUS). Patients with T4, >N2, and/or distant disease were excluded. Results: A total of 156 patients were included in this study. Most patients were white (97 %), male (83 %), and over 60 years of age (51 %). Patients with early disease on pretreatment EUS exhibited improved overall survival compared to patients with late disease (P <0.001). Irrespective of treatment modality, there were no significant differences in overall 5-year survival for patients with early or late disease. Early and late disease patients whose disease responded to neoadjuvant chemotherapy (NAC) had significantly improved overall survival compared to nonresponsive disease (P <0.05). The only negative independent predictors of overall 5-year survival were late stage disease on pretreatment EUS (hazard ratio 2.402, 95 % confidence interval 1.24-4.67, P = 0.01) and late stage disease on final pathological stage (hazard ratio 2.29, 95 % confidence interval 1.22-4.31, P = 0.01). Conclusions: Our data lack statistical power but reveal no difference in survival with the addition of neoadjuvant therapies to surgery for early or late resectable EAC. However, patients with disease that responded to NAC had improved outcomes at 5 years for both groups. Therefore, the prognosis for patients undergoing NAC may be optimized by immediate surgical resection if neoadjuvant therapies do not result in a dramatic clinical response.

AB - Background: There is no consensus on the most effective modality for the treatment of resectable esophageal adenocarcinomas (EAC). We theorized that treatment modality may influence survival differently depending on the stage of disease. Methods: A single-institution, retrospective examination of resectable EAC between 2000 and 2008 was performed. Resectable EAC were stratified into early disease (stage 2a or less) and late disease (stage 2b or more) based on pretreatment endoscopic ultrasound (EUS). Patients with T4, >N2, and/or distant disease were excluded. Results: A total of 156 patients were included in this study. Most patients were white (97 %), male (83 %), and over 60 years of age (51 %). Patients with early disease on pretreatment EUS exhibited improved overall survival compared to patients with late disease (P <0.001). Irrespective of treatment modality, there were no significant differences in overall 5-year survival for patients with early or late disease. Early and late disease patients whose disease responded to neoadjuvant chemotherapy (NAC) had significantly improved overall survival compared to nonresponsive disease (P <0.05). The only negative independent predictors of overall 5-year survival were late stage disease on pretreatment EUS (hazard ratio 2.402, 95 % confidence interval 1.24-4.67, P = 0.01) and late stage disease on final pathological stage (hazard ratio 2.29, 95 % confidence interval 1.22-4.31, P = 0.01). Conclusions: Our data lack statistical power but reveal no difference in survival with the addition of neoadjuvant therapies to surgery for early or late resectable EAC. However, patients with disease that responded to NAC had improved outcomes at 5 years for both groups. Therefore, the prognosis for patients undergoing NAC may be optimized by immediate surgical resection if neoadjuvant therapies do not result in a dramatic clinical response.

UR - http://www.scopus.com/inward/record.url?scp=84880069417&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880069417&partnerID=8YFLogxK

U2 - 10.1245/s10434-012-2766-8

DO - 10.1245/s10434-012-2766-8

M3 - Article

C2 - 23456314

AN - SCOPUS:84880069417

VL - 20

SP - 1660

EP - 1667

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 5

ER -